Sign in

Matthew Dale

Managing Director and Senior Equity Research Analyst at Bank of America

Matthew Dale is a Managing Director and Senior Equity Research Analyst at Bank of America, specializing in healthcare and pharmaceuticals sector research. He covers major pharmaceutical companies and healthcare providers, maintaining a strong performance record with high ratings on industry platforms for stock picks and returns generated. Dale began his analyst career in the early 2000s and has held roles at other leading financial institutions before joining Bank of America, progressing steadily to his current leadership position. He holds FINRA registration and multiple securities licenses, and has been recognized for his research contributions and impactful investment recommendations.

Matthew Dale's questions to LINDE (LIN) leadership

Question · Q3 2025

Matthew Dale from Bank of America questioned the sequential pricing trend, noting it didn't move up, and asked about Linde's confidence in continuing to increase pricing amidst a slower macroeconomic environment.

Answer

CFO Matt White explained that sequential pricing can vary due to contract anniversary and escalation timings, emphasizing that year-over-year pricing of 2% aligns with globally weighted inflation. CEO Sanjiv Lamba added that helium and rare gases, though a small portion of revenue, have been a drag on pricing, particularly in APAC.

Ask follow-up questions

Question · Q3 2025

Matthew Dale inquired about the sequential movement of pricing, noting it didn't move up, and asked about Linde's confidence in continuing to increase prices given the slower macroeconomic environment.

Answer

Matt White, CFO, explained that sequential pricing can vary due to timing differences in contract anniversaries and escalations, preferring to focus on the 2% year-over-year increase which aligns with global inflation. Sanjiv Lamba, CEO, added that helium and rare gases, particularly in APAC, have been a drag on pricing, though their overall impact on enterprise revenue is small.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts